SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001104659-22-109319
Filing Date
2022-10-17
Accepted
2022-10-17 16:05:19
Documents
12
Period of Report
2022-10-17
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2228370d1_8k.htm   iXBRL 8-K 23005
  Complete submission text file 0001104659-22-109319.txt   194408

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA ruby-20221017.xsd EX-101.SCH 3033
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE ruby-20221017_lab.xml EX-101.LAB 34476
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE ruby-20221017_pre.xml EX-101.PRE 22595
6 EXTRACTED XBRL INSTANCE DOCUMENT tm2228370d1_8k_htm.xml XML 3607
Mailing Address 399 BINNEY STREET, SUITE 300 CAMBRIDGE MA 02139
Business Address 399 BINNEY STREET, SUITE 300 CAMBRIDGE MA 02139 617-679-9600
Rubius Therapeutics, Inc. (Filer) CIK: 0001709401 (see all company filings)

IRS No.: 042688109 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38586 | Film No.: 221313814
SIC: 2836 Biological Products, (No Diagnostic Substances)